United States
Content provided by Bausch + Lomb Medical Affairs.
Content provided by Bausch + Lomb Medical Affairs.
Focusing on comprehensive ophthalmic care across anterior and posterior segments. Bausch + Lomb participated through sponsored education and scientific communications highlighting enVista Envy™, MIGS, Teneo™, MIEBO®, and XIIDRA®, with a focus on refractive outcomes, minimally invasive glaucoma surgery, and integrated dry eye management.
PURPOSE: Dry eye disease (DED) is a chronic, multifactorial disease of the ocular surface. Existing prescription medications for DED primarily focus on increasing tear production or reducing inflammation. Perfluorohexyloctane ophthalmic solution (PFHO), the first and only prescription eye drop for DED directly targeting tear evaporation, was introduced in the United States in September 2023. This study describes clinical and demographic characteristics of PFHO early adopters and refill rates after initial prescriptions.
METHODS: Adult patients (≥18 years) newly initiating PFHO from September 1 through November 30, 2023, were identified from the IQVIA Longitudinal Prescription Claims. Eligible patients had linkage to the IQVIA Professional Fee Claims database and a 12-month pre-initiation period ("baseline") for sample characterization. For patients initiating treatment in September or October 2023, refill rates within 60 days were assessed and descriptively compared to a cohort initiating cyclosporine ophthalmic solution 0.05% (CsA, branded or generic).
RESULTS: In total, 7209 patients (79.9% female; mean age, 60.6 years) initiated PFHO. PFHO prescribers were mostly optometrists (54.7%) and ophthalmologists (43.1%). Nearly 100 ocular surface disease ICD-10-CM codes were used to understand DED recording for claims. Only 38.5% of patients had a claim indicative of DED in the baseline period. Common codes indicated aqueous deficient (28.7%), evaporative (11.3%), or inflammatory (16.7%) DED, reflecting its multifactorial nature. Almost half of patients (46.6%) used DED medication during baseline. CsA 0.05% (21.8%) and lifitegrast (17.1%) were most commonly used. The 60-day refill rate for PFHO was 68.7% versus 43.4% for CsA 0.05% initiators (n=75,871) among those with a ≤30 days' supply of their index (initial) prescription.
CONCLUSIONS: Overall, early adopters of PFHO were consistent with the epidemiology of DED. DED may be under-coded in claims, given that <40% of patients had ded claims. the higher refill rate for pfho versus csa 0.05 suggests a higher degree of patient satisfaction and clinical benefit with this new first-in-class treatment for ded.>
PURPOSE: To evaluate visual, refractive, and contrast sensitivity outcomes following laser-assisted in situ keratomileusis (LASIK) using an advanced algorithm.
METHODS: This prospective study included 333 eyes of 168 patients who underwent LASIK using Proscan 1.28 SW ablation algorithm of Technolas Teneo 317 Model 2 (Bausch & Lomb). Preoperatively, all eyes had corrected distance visual acuity (CDVA) of 20/25 or better and manifest refraction spherical equivalent (MRSE) between -1.0 and -11.50 D with or without astigmatism (0.0 to -3.0 D). No nomogram adjustments were made.
RESULTS: At postoperative 9 months, UDVA and CDVA of 20/25 or better were achieved in 97.8% and 100% of eyes, respectively. Gain ≥1 line or no change in CDVA was observed in 98.7% of eyes. Mean MRSE improved from -5.67±2.52 D to -0.04±0.32 D postoperatively; 92.7% and 99.1% of eyes achieved MRSE within ±0.50 D and ±1.00 D, respectively. Residual cylinder of ≤0.50 and ≤1.00 D was achieved in 93% and 99.4% of eyes, respectively. Postoperative mesopic contrast sensitivity (with and without glare) showed significant improvement at 6 and 12 cpd.
CONCLUSION: LASIK performed using Teneo 317 laser's algorithm yielded excellent visual and refractive outcomes that remained stable through postoperative 9 months. Mesopic contrast sensitivity improved significantly.
PURPOSE: To evaluate near vision satisfaction and quality of vision outcomes following implantation of a full range of vision (FRoV) or monofocal intraocular lens (IOL) in cataract patients.
METHODS: Prospective, multicentre, controlled study of enVista Envy (N=110) or enVista monofocal IOL (N=50). Validated NAVQ and QoV questionnaires were used to assess outcomes at 120–180 days postoperative.
RESULTS: The percentage of patients reporting little to no bothersomeness for glares, starbursts, and halos were 95.5%, 93.7% and 88.1% in FRoV versus 96.2%, 100% and 94.2% in monofocals (p>0.1 all cases). Only halos were reported to be more frequent (70.0% vs 94.2%, p=0.0005) and severe (76.3% vs 92.3%, p=0.015). Significantly more FRoV patients performed near-vision tasks spectacle-free (91.7 vs. 51.0%, p<0.0001) and were satisfied with their near-vision 93 vs. 56 p><0.0001).>
CONCLUSION: The novel FRoV IOL led to higher rates of spectacle independence and satisfaction with near vision. While halos were reported to be more frequent and severe, the rate of patients reporting little to no bothersomeness to each of glares, starbursts and halos was not different between FRoV and monofocal groups at 120–180 days.
PURPOSE: Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms of dry eye disease (DED). This study evaluated patient perceptions and satisfaction early in treatment with PFHO.
METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06309953) enrolled adults with a history of DED for ≥6 months, tear film breakup time (TFBUT) ≤5 seconds, Schirmer I test (without anesthesia) score ≥5 mm, Meibomian Gland Dysfunction (MGD) score ≥3 (range, 0-15), and total corneal fluorescein staining (tCFS) score ≥4 and ≤11 (range, 0-15). PFHO was instilled in both eyes 4 times daily for 14 days. Patients completed early outcome surveys during four clinic visits. The early outcomes survey assessed DED symptom severity (8 symptoms), symptom frequency (percentage of time experiencing the symptom), and treatment satisfaction (rated on a visual analog scale from 0-100). Change in symptom frequency from baseline at each post-baseline assessment was analyzed using a 2-sided paired t-test.
RESULTS: A total of 99 patients were enrolled. Mean age was 61.3 years; 85.9% of patients were female. At baseline, mean scores (both eyes) on ocular measures were: TFBUT, 3.6 seconds; Schirmer test, 14.2 mm; MGD score, 8.3; and tCFS, 5.2. The symptom selected as "most bothersome" at baseline was eye dryness (28.3% of patients), blurred vision (17.2%), eye irritation (14.1%), light sensitivity (13.1%), eye tiredness (12.1%), burning/stinging (11.1%), eye itching (4.0%), or eye pain (0%). Mean frequency (percentage of time) experiencing the most bothersome symptom was 77.9% at baseline and decreased to 46.7% at day 3, 41.3% at day 7, and 34.7% at day 14 (a mean reduction of 40.0%, 47.0%, and 55.5%, respectively). Reduction in most bothersome symptom frequency was statistically significant (P<0.0001) at every follow-up assessment. median rating of treatment satisfaction was 83.0 at day 3 86.0 at day 7 and 90.0 at day 14.>
CONCLUSIONS: Early in the course of treatment with PFHO, patients with DED experienced significant reductions in the frequency of dry eye symptoms. Treatment satisfaction with PFHO was high.
Get Support
Contact UsContact a
Representative
Submit a
Medical Inquiry
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.
